Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated ...

Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported ...

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") , a clinical-stage biotechnology company leveraging its proprietary DiffuSpheretm technology designed to optimize drug delivery for ...

Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome ...

Posterior scleritis is a rare but potentially sight-threatening condition that commonly causes diagnostic confusion due to its variable and perplexing clinical symptoms and signs. We present a case of ...

1 Day WBA -0.80% DJIA -0.62% S&P 500 -1.07% Retail/Wholesale 1.53% ...